Premium
Endoscopic bariatric therapies for obesity: a review
Author(s) -
Staudenmann Dominic A,
Sui Zhixian,
Saxena Payal,
Kaffes Arthur J,
Marinos George,
Kumbhari Vivek,
Aepli Patrick,
Sartoretto Adrian
Publication year - 2021
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/mja2.51179
Subject(s) - weight loss , medicine , overweight , obesity , randomized controlled trial , surgery , balloon , management of obesity , endoscopy , general surgery
Summary▪ Obesity is reaching pandemic proportions globally, with overweight or obesity affecting at least two‐thirds of Australian adults. ▪ Bariatric surgery is an effective weight loss strategy but is constrained by high resource requirements and low patient acceptance. ▪ Multiple endoscopic bariatric therapies have matured, with well established and favourable safety and efficacy profiles in multiple randomised controlled trials (RCTs), and are best used within a multidisciplinary setting as an adjuvant to lifestyle intervention. ▪ Three types of intragastric balloon are currently in use in Australia offering average total weight loss ranging from 10% to 18%, with others available internationally. ▪ Endoscopic sleeve gastroplasty produces average total weight loss of 15–20% with low rates of severe complications, with RCT data anticipated in December 2021. ▪ Bariatric and metabolic endoscopy is rapidly evolving, with many novel, promising therapies currently under investigation.